Use Of Therapeutic Monoclonal Antibodies Increasing In Europe

Main Category: Pharma Industry / Biotech Industry
Also Included In: Infectious Diseases / Bacteria / Viruses;  Public Health
Article Date: 16 Sep 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Despite high therapy costs and drug format limitations, the popularity of monoclonal antibodies (mAbs) is on the rise. Physicians are increasingly adopting mAbs because of their superior side effect profile, and continued research is expected to yield more innovative products.

New analysis from Frost & Sullivan , European Therapeutic Monoclonal Antibody Markets, finds that the markets earned revenues of $7.9 billion in 2007 and estimates this to reach $22.2 billion in 2014.

"A strong R&D pipeline along with expanding applications of mAbs in new therapeutic and disease areas will accelerate market growth," notes Frost & Sullivan Senior Research Analyst Arun A.K. "The increasing number of alliances between pharma and biotech companies will advance research and technological initiatives, a factor key to the continued expansion of the market."

The financial success stories of top mAbs have attracted many companies and have resulted in mAbs being identified as a key growth area. Companies are relying on research to develop mAbs and associated technologies for commercial opportunities.

Market participants will however have to meet key challenges to take advantage of opportunities. Firstly, the public healthcare system is under tremendous pressure to support the therapy cost of mAbs. Due to their high costs, the target population for treatment is also likely to be limited. Moreover, the inherent challenges associated with development and manufacturing of mAbs is likely to remain high over the long term.

"High treatment costs and inherent limitations in the antibody format are constraining market expansion," explains Arun. "The heightened focus on small molecule drugs will also challenge the growth of this market over the next five to seven years."

Investing in research and moving manufacturing units to cheaper destinations will help overcome the high development costs associated with mAbs. Building a recognisable brand will enable companies to popularise mAbs and reduce the risk posed by alternate therapies in the future.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European therapeutic monoclonal antibody markets, then send an e-mail to Patrick Cairns, Corporate Communications, at pcairns_pr@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

European Therapeutic Monoclonal Antibody Markets is part of the Pharmaceutical and Biotechnology Growth Partnership Services Programme, which also includes research in the following markets: European Drug Delivery Markets, European Biosimilars Market and European CMO Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Frost & Sullivan